Unnamed: 0,title,date,stock,sentiment
437322.0,Esperion Announces Commercial Availability Of NEXLIZET Tablets And Ushers In New Era Of Oral Combination Medicine For LDL-Cholesterol Lowering,2020-06-04 07:08:00-04:00,ESPR,negative
437323.0,"The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs",2020-06-02 07:45:00-04:00,ESPR,negative
437324.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,ESPR,negative
437325.0,"Jefferies Maintains Buy on Esperion Therapeutics, Lowers Price Target to $70",2020-05-07 13:32:00-04:00,ESPR,negative
437326.0,"Esperion Therapeutics Q1 EPS $(2.840) Beats $(3.290) Estimate, Sales $1.840M Beat $520.000K Estimate",2020-05-06 16:28:00-04:00,ESPR,neutral
437327.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,ESPR,positive
437328.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ESPR,neutral
437329.0,"Esperion Announces Agreement With Otsuka Pharmaceutical Co., Ltd. For Development And Commercialization Of NEXLETOL And NEXLIZET Tablets In Japan; Esperion To Receive $60M Up Front, Up To $510M In Milestones",2020-04-20 07:02:00-04:00,ESPR,positive
437330.0,"Northland Capital Markets Maintains Market Perform on Esperion Therapeutics, Lowers Price Target to $42",2020-04-16 12:57:00-04:00,ESPR,negative
437331.0,Esperion Therapeutics shares are trading higher after the company announced European Commission approval of its NILEMDO tablet.,2020-04-06 08:26:00-04:00,ESPR,positive
437332.0,"Esperion Announces European Commission Approval of the NILEMDO Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia, Says Will Receive $150M Milestone Payment Upon First Commercial Sale",2020-04-06 07:03:00-04:00,ESPR,positive
437333.0,"B of A Securities Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces Price Target to $50",2020-04-01 12:00:00-04:00,ESPR,positive
437334.0,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",2020-03-31 08:26:00-04:00,ESPR,negative
437335.0,Esperion Reports Commercial Availability Of NEXLETOL Tablet,2020-03-30 16:24:00-04:00,ESPR,neutral
437336.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,ESPR,neutral
437337.0,Citigroup Upgrades Esperion Therapeutics to Buy,2020-03-17 05:30:00-04:00,ESPR,neutral
437338.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2020-03-02 16:46:00-05:00,ESPR,neutral
437339.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,ESPR,neutral
437340.0,"JP Morgan Maintains Neutral on Esperion Therapeutics, Raises Price Target to $47",2020-02-28 09:51:00-05:00,ESPR,positive
437341.0,Esperion Therapeutics Q4 EPS $(2.26) Down From $(2.24) YoY,2020-02-27 07:59:00-05:00,ESPR,neutral
437342.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ESPR,positive
437343.0,Esperion Reports FDA Approval Of NEXLIZET Tablet Once-Daily For Non-Statin LDL-Cholesterol Lowering Medicine,2020-02-26 17:33:00-05:00,ESPR,positive
437344.0,Esperion Therapeutics Receives FDA Approval Of Nexlizet,2020-02-26 14:57:00-05:00,ESPR,positive
437345.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,ESPR,negative
437346.0,"Needham Maintains Strong Buy on Esperion Therapeutics, Raises Price Target to $158",2020-02-24 11:37:00-05:00,ESPR,positive
437347.0,A Peek Into The Markets: Dow Futures Slump Over 700 Points As COVID-19 Spreads Globally,2020-02-24 05:59:00-05:00,ESPR,neutral
437348.0,Northland Securities Downgrades Esperion Therapeutics to Market Perform,2020-02-24 05:14:00-05:00,ESPR,positive
437349.0,94 Biggest Movers From Friday,2020-02-24 04:53:00-05:00,ESPR,neutral
437350.0,"8 Stocks To Watch For February 24, 2020",2020-02-24 04:32:00-05:00,ESPR,neutral
437351.0,Esperion Press Release Confirms FDA Approval Of NEXLETOL,2020-02-21 16:39:00-05:00,ESPR,positive
437352.0,Esperion Therapeutics Shares Dip Lower As Traders Circulate Label For NEXLETOL,2020-02-21 14:35:00-05:00,ESPR,neutral
437353.0,Esperion Therapeutics Receives FDA Approval For NEXLETOL,2020-02-21 14:22:00-05:00,ESPR,positive
437354.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,ESPR,negative
437355.0,30 Stocks Moving in Tuesday's Pre-Market Session,2020-02-18 07:13:00-05:00,ESPR,neutral
437356.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,ESPR,positive
437357.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,ESPR,negative
437358.0,"Citigroup Downgrades Esperion Therapeutics to Neutral, Raises Price Target to $82",2020-02-14 05:54:00-05:00,ESPR,neutral
437359.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-13 10:26:00-05:00,ESPR,neutral
437360.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ESPR,negative
437361.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,ESPR,neutral
437362.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,ESPR,positive
437363.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,ESPR,neutral
437364.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,ESPR,positive
437365.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2020-02-03 13:30:00-05:00,ESPR,neutral
437366.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,ESPR,neutral
437367.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,ESPR,neutral
437368.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,ESPR,neutral
437369.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,ESPR,positive
437370.0,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering",2020-01-07 07:57:00-05:00,ESPR,negative
437371.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,ESPR,negative
437372.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,ESPR,negative
437373.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,ESPR,neutral
437374.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,ESPR,neutral
437375.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,ESPR,negative
437376.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,ESPR,negative
437377.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,ESPR,neutral
437378.0,Esperion Therapeutics Option Alert: Jan 17 $55 Calls at the Ask: 500 @ $1.65 vs 361 OI; Ref=$51.325,2019-12-17 13:40:00-05:00,ESPR,positive
437379.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,ESPR,neutral
437380.0,Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at AHA 2019 Scientific Sessions,2019-11-17 19:50:00-05:00,ESPR,negative
437381.0,Esperion Highlights Publication In Journal Of American Medical Association Of Bempedoic Acid Phase 3 Study 2 Results,2019-11-12 11:07:00-05:00,ESPR,neutral
437382.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,ESPR,positive
437383.0,"Esperion Therapeutics Q3 EPS $(2.52) Misses $(1.95) Estimate, Sales $981K Beat $900K Estimate",2019-11-06 07:38:00-05:00,ESPR,negative
437384.0,"Stifel Nicolaus Maintains Buy on Esperion Therapeutics, Lowers Price Target to $70",2019-09-18 08:04:00-04:00,ESPR,negative
437385.0,"Benzinga's Top Upgrades, Downgrades For September 16, 2019",2019-09-16 10:17:00-04:00,ESPR,positive
437386.0,"Goldman Sachs Upgrades Esperion Therapeutics to Neutral, Lowers Price Target to $45",2019-09-16 07:43:00-04:00,ESPR,negative
437387.0,"The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug",2019-09-05 08:12:00-04:00,ESPR,neutral
437388.0,Esperion Highlights Completion Of Patient Enrollment In Global CLEAR Cardiovascular Outcomes Trial For Bempedoic Acid,2019-09-05 07:40:00-04:00,ESPR,positive
437389.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-04 11:39:00-04:00,ESPR,negative
437390.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,ESPR,positive
437391.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-29 08:40:00-04:00,ESPR,neutral
437392.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,ESPR,negative
437393.0,"Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster",2019-08-20 17:35:00-04:00,ESPR,positive
437394.0,"Esperion Therapeutics Earlier Reported Q2 EPS $(2.01) Misses $(1.86) Estimate, Sales $982K Beat $930K Estimate; Expects Full-Year 2019 Net Increase In Cash Of Approximately $90 To $100 Million",2019-08-08 10:44:00-04:00,ESPR,positive
437395.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,ESPR,neutral
437396.0,"Esperion Shares Now Open For Trade, But Not Yet Seeing Updated Last Price",2019-06-26 16:41:00-04:00,ESPR,positive
437397.0,Esperion Shares To Resume Trade At 4:40 p.m. EDT,2019-06-26 16:15:00-04:00,ESPR,positive
437398.0,Esperion Says Initial Mid-Single Digit Repayment Rate On US Sales To Step Down To Less Than 1% Upon Certain Sales Milestones,2019-06-26 16:13:00-04:00,ESPR,positive
437399.0,Esperion Has Reacquired 100% Of Sales Rights Upon Repayment Completion,2019-06-26 16:12:00-04:00,ESPR,neutral
437400.0,"UPDATE: Esperion To Receive $125M Upfront Payment, $25M Upon FDA Approval, $50M At Esperion's Option After Launch",2019-06-26 16:12:00-04:00,ESPR,positive
437401.0,Esperion Reports $200M Funding Deal With Oberland,2019-06-26 16:11:00-04:00,ESPR,neutral
437402.0,Esperion Shares Halted News Pending,2019-06-26 16:05:00-04:00,ESPR,positive
437403.0,"Benzinga's Top Upgrades, Downgrades For May 29, 2019",2019-05-29 09:26:00-04:00,ESPR,positive
437404.0,28 Stocks Moving In Wednesday's Pre-Market Session,2019-05-29 08:16:00-04:00,ESPR,neutral
437405.0,"Goldman Sachs Downgrades Esperion Therapeutics to Sell, Announces $50 Price Target",2019-05-29 07:37:00-04:00,ESPR,neutral
437406.0,Esperion Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2019-05-08 11:04:00-04:00,ESPR,positive
437407.0,"Esperion Therapeutics Q1 EPS $3.07 Beats $0.97 Estimate, Sales $145.42M Beat $79.03M Estimate",2019-05-08 07:07:00-04:00,ESPR,neutral
437408.0,44 Biggest Movers From Yesterday,2019-05-07 05:49:00-04:00,ESPR,neutral
437409.0,Esperion Therapeutics Shares Tick Higher On Heavy Volume Over Last Few Mins. As Hearing Bank Of America Upgraded Stock,2019-05-06 12:57:00-04:00,ESPR,positive
437410.0,30 Stocks Moving In Monday's Mid-Day Session,2019-05-06 12:23:00-04:00,ESPR,neutral
437411.0,Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications,2019-05-06 10:33:00-04:00,ESPR,positive
437412.0,Esperion Therapeutics shares are trading higher after the FDA accepted the company's NDAs for Bempedoic Acid and the Ezetimibe combination tablet.,2019-05-06 09:11:00-04:00,ESPR,positive
437413.0,26 Stocks Moving In Monday's Pre-Market Session,2019-05-06 08:07:00-04:00,ESPR,neutral
437414.0,Esperion Announces FDA Acceptance of NDAs for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review,2019-05-05 17:33:00-04:00,ESPR,positive
437415.0,"Benzinga's Top Upgrades, Downgrades For April 26, 2019",2019-04-26 08:48:00-04:00,ESPR,positive
437416.0,"Goldman Sachs Upgrades Esperion Therapeutics, Inc. - Common Stock to Neutral",2019-04-26 06:24:00-04:00,ESPR,neutral
437417.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,ESPR,positive
437418.0,Esperion Highlights Results From Phase 3 Trial Published In Journal of the American Heart Association: Showed 'Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant',2019-04-01 16:22:00-04:00,ESPR,negative
437419.0,A New ETF For An Untapped Real Estate Market,2019-03-23 14:33:00-04:00,ESPR,neutral
437420.0,70 Biggest Movers From Yesterday,2019-03-20 05:36:00-04:00,ESPR,neutral
437421.0,Esperion Reports Late-Breaking Publication Of Final Results Of Bempedoic Acid Pivotal Phase 3 Study 2 At American College of Cardiology 2019 Scientific Sessions,2019-03-18 09:21:00-04:00,ESPR,neutral
437422.0,Esperion Highlights Publication Of Bempedoic Acid Study 1 Results In The New England Journal Of Medicine,2019-03-13 17:06:00-04:00,ESPR,neutral
437423.0,5 Biggest Price Target Changes For Wednesday,2019-03-13 09:51:00-04:00,ESPR,neutral
437424.0,"Benzinga's Top Upgrades, Downgrades For March 13, 2019",2019-03-13 09:13:00-04:00,ESPR,positive
437425.0,"JP Morgan Upgrades Esperion Therapeutics to Neutral, Raises Price Target to $47",2019-03-13 08:30:00-04:00,ESPR,positive
437426.0,Esperion Announces Presentation Of Bempedoic Acid Pivotal Phase 3 Study 2 Results In Late-Breaking Clinical Trial Session At American College Of Cardiology 2019 Scientific Sessions,2019-03-04 08:14:00-05:00,ESPR,neutral
437427.0,Esperion Therapeutics Q4 EPS $(2.24) Misses $(1.42) Estimate,2019-02-28 17:20:00-05:00,ESPR,negative
437428.0,Esperion Announces Submissions Of Two NDAs And Official Completion Of Two MAA Validations For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Combination Tablet,2019-02-28 07:29:00-05:00,ESPR,neutral
437429.0,26 Stocks Moving In Tuesday's Pre-Market Session,2019-02-12 08:25:00-05:00,ESPR,neutral
437430.0,58 Biggest Movers From Friday,2019-01-07 04:17:00-05:00,ESPR,neutral
437431.0,22 Stocks Moving In Friday's Pre-Market Session,2019-01-04 08:10:00-05:00,ESPR,neutral
437432.0,"Esperion Reports Deal With Daiichi Sankyo Europe To Commercialize Bempedoic Acid In Europe, Will Receive $300M Upfront, Near-Term Milestones, Will Be Eligible For $900M In Total Milestones",2019-01-04 07:09:00-05:00,ESPR,neutral
437433.0,"Goldman Sachs Initiates Coverage On Esperion Therapeutics with Sell Rating, Announces $45 Price Target",2018-12-13 09:28:00-05:00,ESPR,neutral
437434.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,ESPR,neutral
437435.0,Esperion Therapeutics Q3 EPS $(1.86) Misses $(1.63) Estimate,2018-11-01 17:28:00-04:00,ESPR,negative
437436.0,"JMP Securities Out Positive On Esperion Therapeutics; Firm Says Conference Call Reaffirms 'Positive' BA Phase 3 Results And 'Compelling' Product Profile, Reaffirms Market Outperform Rating And $153 PT",2018-10-29 14:14:00-04:00,ESPR,positive
437437.0,42 Stocks Moving In Monday's Mid-Day Session,2018-10-29 12:21:00-04:00,ESPR,neutral
437438.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-29 08:25:00-04:00,ESPR,neutral
437439.0,71 Biggest Movers From Friday,2018-10-29 05:33:00-04:00,ESPR,neutral
437440.0,UPDATE: Esperion Announces Bempedoic Acid Met Safety and Tolerability Endpoints in 52-Week Study,2018-10-28 17:16:00-04:00,ESPR,positive
437441.0,Esperion Announces Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP Reduction in Final Pivotal Phase 3 Study,2018-10-28 17:13:00-04:00,ESPR,negative
437442.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,ESPR,neutral
437443.0,30 Stocks Moving In Friday's Pre-Market Session,2018-10-26 08:06:00-04:00,ESPR,neutral
437444.0,48 Biggest Movers From Yesterday,2018-10-17 05:53:00-04:00,ESPR,neutral
437445.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-10-16 12:46:00-04:00,ESPR,neutral
437446.0,"Benzinga's Top Upgrades, Downgrades For October 16, 2018",2018-10-16 09:14:00-04:00,ESPR,positive
437447.0,"BTIG Research Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces $82 Price Target",2018-10-16 06:19:00-04:00,ESPR,neutral
437448.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,ESPR,neutral
437449.0,20 Stocks Moving In Monday's Pre-Market Session,2018-10-01 08:03:00-04:00,ESPR,neutral
437450.0,"Esperion Resumes Trade, Now Up ~1.85% At $49.99/Share",2018-08-27 07:32:00-04:00,ESPR,neutral
437451.0,"Esperion Announces That Bempedoic Acid/Ezetimibe Combo Pill Achieved An Additional 35% LDL-C Loweirng IN Patients On Maximally Tolerated Statins, Treatment Appeared To Be As Safe And Well-Tolerated As Ezetimibe Alone",2018-08-27 07:03:00-04:00,ESPR,positive
437452.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results",2018-08-26 15:40:00-04:00,ESPR,neutral
437453.0,Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at #ESCCongress,2018-08-25 08:39:00-04:00,ESPR,positive
437454.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings",2018-08-19 12:00:00-04:00,ESPR,neutral
437455.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2018",2018-08-17 08:59:00-04:00,ESPR,positive
437456.0,"Citigroup Upgrades Esperion Therapeutics to Buy, Raises Price Target to $75",2018-08-17 07:43:00-04:00,ESPR,neutral
437457.0,Esperion Therapeutics Q2 EPS $(1.71) Misses $(1.70) Estimate,2018-08-02 07:04:00-04:00,ESPR,negative
437458.0,"Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors",2018-07-16 07:45:00-04:00,ESPR,neutral
437459.0,Northland Securities Downgrades Esperion Therapeutics to Market Perform,2018-07-11 09:05:00-04:00,ESPR,positive
437460.0,Esperion Shares Fall ~2.4% Under $44 Over Last Few Mins; Shares Now Down 2.4% For Session; Co. Currently Hosting Analyst/Investor Day,2018-07-10 12:08:00-04:00,ESPR,positive
437461.0,"Esperion Therapeutics 10%+ Owner BB Biotech Buys 60,000 @ Avg Price: $38.57",2018-06-25 12:46:00-04:00,ESPR,neutral
437462.0,Esperion Therapeutics Option Alert: Jul 20 $30 Puts at the Ask: 585 @ $0.451 vs 666 OI; Earnings 8/7 Before Open [est] Ref=$40.87,2018-06-15 09:46:00-04:00,ESPR,positive
437463.0,"Biotech Target NV Buys 60,000 Of Esperion Therapeutics  @$37.79",2018-06-11 15:01:00-04:00,ESPR,neutral
437464.0,"Esperion Therapeutics 10%+ Owner BB BIOTECH AG (10%+) Buys 60,000 @ Avg Price: $38.47",2018-06-07 14:37:00-04:00,ESPR,neutral
437465.0,"Esperion Shares Resumed Trade at 8:45, Now Up 2.3% Premarket",2018-05-23 08:50:00-04:00,ESPR,positive
437466.0,Esperion Therapeutics Shares To Resume Trade At 8:45 a.m. EDT,2018-05-23 08:20:00-04:00,ESPR,positive
437467.0,UPDATE: Esperion Says Phase 3 Study Of Bempedoic Acid 'achieved a significantly greater reduction of 25% in high-sensitivity C-reactive protein',2018-05-23 08:16:00-04:00,ESPR,positive
437468.0,Esperion Therapeutics Reports Phase 3 Study Of Bempedoic Acid Met Primary Endpoint,2018-05-23 08:15:00-04:00,ESPR,neutral
437469.0,Esperion Therapeutics Shares Halted News Pending,2018-05-23 08:10:00-04:00,ESPR,positive
437470.0,"Esperion Shares Rebound From Monday's Weakness, Up 5.2%; Shares Fell Mon. As CEO's Absence From UBS Conference Noted By Traders Passing Tentative Schedule Listing Co. As A Monday Presenter; Tuesday Press Release Confirms CEO To Present Wednesday",2018-05-22 13:28:00-04:00,ESPR,positive
437471.0,"Esperion Therapeutics Shares Down 10.4%, No Apparent News: Note: CEO Set To Appear At 1:30 PM EST At UBS Global Healthcare Conference",2018-05-21 15:24:00-04:00,ESPR,neutral
437472.0,"12 Biggest Movers Of The Week: Snap, Tenet, Wayfair And More",2018-05-04 16:48:00-04:00,ESPR,neutral
437473.0,"Credit Suisse Maintains Outperform on Esperion Therapeutics, Lowers Price Target to $73.00",2018-05-04 10:20:00-04:00,ESPR,positive
437474.0,55 Biggest Movers From Yesterday,2018-05-04 04:41:00-04:00,ESPR,neutral
437475.0,37 Stocks Moving In Thursday's Mid-Day Session,2018-05-03 13:39:00-04:00,ESPR,neutral
437476.0,"Esperion Shares Bouncing Off Low's Of The Day, Now Down ~25% At $34.20/Share",2018-05-03 12:36:00-04:00,ESPR,positive
437477.0,8 Biggest Price Target Changes For Thursday,2018-05-03 11:32:00-04:00,ESPR,neutral
437478.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2018",2018-05-03 11:26:00-04:00,ESPR,positive
437479.0,"Benzinga Pro's Most-Searched Tickers For Morning Of May 3, 2018",2018-05-03 11:18:00-04:00,ESPR,neutral
437480.0,Analysts Defend Esperion As Shares Sell Off Sharply,2018-05-03 11:17:00-04:00,ESPR,positive
437481.0,JP Morgan Downgrades Esperion Therapeutics to Underweight,2018-05-03 08:58:00-04:00,ESPR,positive
437482.0,"Deutsche Bank Maintains Buy on Esperion Therapeutics, Lowers Price Target to $75.00",2018-05-03 08:54:00-04:00,ESPR,negative
437483.0,55 Biggest Movers From Yesterday,2018-05-03 04:42:00-04:00,ESPR,neutral
437484.0,Mid-Afternoon Market Update: Community Health Systems Surges Following Q1 Beat; TC PipeLines Shares Slide,2018-05-02 15:01:00-04:00,ESPR,positive
437485.0,"Benzinga's Top Analyst Calls From May 2, 2018",2018-05-02 13:55:00-04:00,ESPR,positive
437486.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-05-02 13:30:00-04:00,ESPR,neutral
437487.0,"Bank of America Downgrades Esperion And Lowers Price Target From $95 To $44 As They Believe Death Imbalance May Raise Concern From FDA, Firm Lowers Drug Penetration In Target Patient Population And Decrease Likelihood Of FDA Approval",2018-05-02 13:28:00-04:00,ESPR,negative
437488.0,Bank of America Downgrades Esperion Therapeutics to Underperform,2018-05-02 13:25:00-04:00,ESPR,neutral
437489.0,Traders Circulating Chatter That  Bank Of America Downgrades Esperion,2018-05-02 13:23:00-04:00,ESPR,neutral
437490.0,"Esperion Shares Down 31.4% Wed.; Needham Issues Mid-Day Comments In Note, Says 'We Remain Confident in Efficacy and Safety Profile of Bempedoic Acid'; Maintains Strong Buy Rating, $94 Price Target",2018-05-02 13:06:00-04:00,ESPR,positive
437491.0,Mid-Day Market Update: Nanometrics Rises On Earnings Beat; Esperion Therapeutics Shares Drop,2018-05-02 12:47:00-04:00,ESPR,neutral
437492.0,"'The question is not if $ESPR will need to run a CVOT. They will, just like $REGN and $AMGN. They key question is — when? 

$ESPR bulls believe CVOT will be done post approval. Bears say CVOT before.'-STAT's Adam Feuerstein",2018-05-02 12:28:00-04:00,ESPR,positive
437493.0,Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns,2018-05-02 11:56:00-04:00,ESPR,positive
437494.0,"JMP Out Defending Esperion, Says  There's No Concern In Death Imbalance In Phase 3 Long-Term Study Of Bempedoic Acid, Firm Agrees With Management Commentary That Fatalities In Study 1 Weren't Related To Study Drug",2018-05-02 10:40:00-04:00,ESPR,negative
437495.0,Mid-Morning Market Update: Markets Mixed; Apple Earnings Top Expectations,2018-05-02 10:22:00-04:00,ESPR,positive
437496.0,"UPDATE: Cowen On Esperion: 'Data presented suggests the top line is fine, however mgmt did a poor job communicating details of the imbalances'; Firm Maintains Buy Rating",2018-05-02 10:14:00-04:00,ESPR,negative
437497.0,"Esperion Shares Down 22.7% For Session, Up 22% From Session Lows; Hearing Cowen Out Defending Stock, Says 'Magnitude Of Move Is Overdone'",2018-05-02 10:13:00-04:00,ESPR,positive
437498.0,Esperion Therapeutics Q1 EPS $(1.73) Misses $(1.56) Estimate,2018-05-02 07:54:00-04:00,ESPR,negative
437499.0,Esperion Shares To Resume Trade At 8 a.m. EDT,2018-05-02 07:37:00-04:00,ESPR,positive
437500.0,"Esperion Reports Top-Line Results From Pivotal Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint, Achieveded Added 20% On-Treatment LDL-C Lowering On Background Maximally Tolerated Statin Therapy",2018-05-02 07:36:00-04:00,ESPR,positive
437501.0,Esperion Shares Halted News Pending,2018-05-02 07:25:00-04:00,ESPR,positive
437502.0,"Chardan Capital Maintains Neutral on Esperion Therapeutics, Raises Price Target to $100.00",2018-03-27 15:42:00-04:00,ESPR,neutral
437503.0,Esperion Phase 2 Study of Bempedoic Acid Met its Primary Endpoint,2018-03-27 07:34:00-04:00,ESPR,neutral
437504.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-26 07:48:00-04:00,ESPR,neutral
437505.0,25 Stocks Moving In Monday's Pre-Market Session,2018-03-12 08:04:00-04:00,ESPR,neutral
437506.0,28 Stocks Moving In Wednesday's Pre-Market Session,2018-03-07 08:06:00-05:00,ESPR,neutral
437507.0,Esperion Shares To Resume Trade At 8 a.m. EST,2018-03-07 07:55:00-05:00,ESPR,positive
437508.0,Esperion Therapeutics to Resume Trading at 8:00 AM ET,2018-03-07 07:41:00-05:00,ESPR,neutral
437509.0,Esperion Reports Phase 3 Study Of 1002-048 Has Met Primary Endpoint With LDL-C Lowering Totaling 28% With p<0.001,2018-03-07 07:32:00-05:00,ESPR,negative
437510.0,Esperion Shares Halted News Pending,2018-03-07 07:25:00-05:00,ESPR,positive
437511.0,7 Biotech Stocks With Clinical Trial Outcomes In March,2018-03-05 12:01:00-05:00,ESPR,neutral
437512.0,"UBS Maintains Neutral on Esperion Therapeutics, Raises price target to $90.00",2018-02-21 10:02:00-05:00,ESPR,neutral
437513.0,"JP Morgan Maintains Neutral on Esperion Therapeutics, Raises price target to $65.00",2018-02-21 08:46:00-05:00,ESPR,positive
437514.0,Esperion Reports Q4 EPS $(1.44) vs $(1.79) Est.,2018-02-20 07:35:00-05:00,ESPR,neutral
437515.0,42 Biggest Movers From Yesterday,2018-01-25 05:22:00-05:00,ESPR,neutral
437516.0,Citi Downgrades Esperion As Hope Of Acquisition Dwindles,2018-01-22 09:58:00-05:00,ESPR,positive
437517.0,"Citigroup Downgrades Esperion Therapeutics to Neutral, Raises Price Target to $96.00",2018-01-22 07:48:00-05:00,ESPR,neutral
437518.0,"Credit Suisse Initiates Coverage On Esperion Therapeutics with Outperform Rating, Announces $103.00 Price Target",2018-01-17 16:55:00-05:00,ESPR,positive
437519.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,ESPR,positive
437520.0,Bank of America Upgrades Esperion Therapeutics to Buy,2018-01-05 08:33:00-05:00,ESPR,neutral
437521.0,Esperion Therapeutics Q3 EPS $(1.86) vs $(1.79) Est.,2017-11-07 08:10:00-05:00,ESPR,neutral
437522.0,"Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill, Top-Line Results Expected by the Fourth Quarter of 2018",2017-11-06 16:31:00-05:00,ESPR,neutral
437523.0,"Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More",2017-10-18 07:45:00-04:00,ESPR,positive
437524.0,Esperion Therapeutics Holding Analyst/Investor Day Today,2017-10-17 08:37:00-04:00,ESPR,neutral
437525.0,"The Week Ahead: Earnings, Earnings, And More Earnings",2017-10-16 10:49:00-04:00,ESPR,neutral
437526.0,Meditor Group Reports 8.2% Stake In Esperion Therapeutics,2017-08-21 13:43:00-04:00,ESPR,neutral
437527.0,"Benzinga's Top Upgrades, Downgrades For August 9, 2017",2017-08-09 09:24:00-04:00,ESPR,positive
437528.0,The Market In 5 Minutes,2017-08-09 08:34:00-04:00,ESPR,neutral
437529.0,Jefferies Upgrades Esperion Therapeutics to Buy,2017-08-09 07:15:00-04:00,ESPR,neutral
437530.0,Jefferies Upgrades Esperion to Buy from Hold; Raises PT to $85 from $55,2017-08-09 04:38:00-04:00,ESPR,neutral
437531.0,Esperion Reports Offering Of $150M In Common Stock,2017-08-08 16:32:00-04:00,ESPR,neutral
437532.0,18 Biggest Mid-Day Gainers For Tuesday,2017-08-08 12:34:00-04:00,ESPR,neutral
437533.0,Esperion Sees FY17 Net Cash Used In Operating Activities ~$125M-$135M,2017-08-08 08:29:00-04:00,ESPR,neutral
437534.0,Esperion Therapeutics Reports Q2 EPS $(1.92) vs $(1.61) Est.,2017-08-08 08:28:00-04:00,ESPR,neutral
437535.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-08-08 08:06:00-04:00,ESPR,neutral
437536.0,Esperion Pharma Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin Meets Primary Endpoint,2017-08-08 07:34:00-04:00,ESPR,neutral
437537.0,Esperion Announces Initiation Of Phase 2 Study of Bempedoic Acid Added-On To PCSK9 Inhibitor,2017-07-26 16:38:00-04:00,ESPR,negative
437538.0,"Jefferies Initiates Coverage On Esperion Therapeutics with Hold Rating, Announces $55.00 Price Target",2017-07-11 07:42:00-04:00,ESPR,neutral
437539.0,Benzinga's Option Alert Recap From June 28,2017-06-28 16:12:00-04:00,ESPR,positive
437540.0,Option Alert: Esperion Dec 27 Put; 2000 @Bid @$1.07; Ref=$48.21,2017-06-28 14:43:00-04:00,ESPR,positive
437542.0,Esperion Announces FDA Confirmation Of Regulatory Pathway To Approval For Bempedoic Acid and Ezetimibe,2017-06-26 16:11:00-04:00,ESPR,positive
437543.0,Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold,2017-06-23 09:54:00-04:00,ESPR,neutral
437544.0,"Deutsche Bank Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces $48.00 Price Target",2017-06-23 07:31:00-04:00,ESPR,neutral
437545.0,Esperion Drops to Low of $32.60 on Volume,2017-06-16 15:55:00-04:00,ESPR,negative
437546.0,Esperion Therapeutics Says a Report With Inaccurate Information was Issued Last Thursday,2017-05-22 08:07:00-04:00,ESPR,neutral
437547.0,Watch These 5 Huge Put Purchases In Monday Trade,2017-05-22 04:40:00-04:00,ESPR,positive
437548.0,Benzinga's Option Alert Recap From May 19,2017-05-19 17:00:00-04:00,ESPR,positive
437550.0,Esperion Reports Q1 EPS $(1.80) vs $(0.65) In Same Qtr. Last Year,2017-05-04 18:01:00-04:00,ESPR,neutral
437551.0,Esperion Shares Make Near-Term Parabolic Move Over $38.50 Level; Stock Off Session Highs But Still Up 2.2% for Session; Hearing MoneyShow Blog Has Mentioned Name Positively,2017-04-12 10:23:00-04:00,ESPR,positive
437552.0,Cardiovascular Players Could Be Eyeing Esperion,2017-04-10 11:53:00-04:00,ESPR,neutral
437553.0,Source Familiar with Matter Tells Benzinga Esperion Therapeutics Could Be Drawing Takeover Interest from Player in Cardiovascular Space,2017-04-10 10:55:00-04:00,ESPR,positive
437554.0,Watch These 6 Huge Put Purchases In Monday Trade,2017-04-10 06:51:00-04:00,ESPR,positive
437555.0,Benzinga's Option Alert Recap From April 7,2017-04-07 16:30:00-04:00,ESPR,positive
437556.0,Option Alert: Esperion Sep 13.0 Puts: 1374 @  ASK  $0.25: 2000 traded vs 2033 OI:  Earnings 5/3 Before Open [est]  $35.46 Ref,2017-04-07 14:24:00-04:00,ESPR,positive
437557.0,13G Filing Shows Boxer Capital Reporting 5.3% Stake In Esperion Therapeutics,2017-03-23 16:41:00-04:00,ESPR,neutral
437558.0,Benzinga's Option Alert Recap From March 21,2017-03-21 16:45:00-04:00,ESPR,positive
437559.0,Option Alert: Esperion Sep 22.0 Puts: 500 @  ASK  $1.00: 767 traded vs 881 OI:  Earnings 5/3 Before Open (est)  $39.85 Ref,2017-03-21 11:17:00-04:00,ESPR,positive
437560.0,Esperion Therapeutics Rockets 70% Higher After Big Selloff,2017-03-20 14:40:00-04:00,ESPR,neutral
437561.0,Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide,2017-03-20 14:34:00-04:00,ESPR,positive
437562.0,Needham Raises Target on Esperion Therapeutics from $25 to $58,2017-03-20 12:55:00-04:00,ESPR,neutral
437563.0,12 Biggest Mid-Day Gainers For Monday,2017-03-20 12:38:00-04:00,ESPR,neutral
437564.0,Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop,2017-03-20 12:13:00-04:00,ESPR,positive
437565.0,"PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter",2017-03-20 10:47:00-04:00,ESPR,neutral
437566.0,"In Response To Adam Feuerstein's Tweet On Esperion, Forbes Reporter Matthew Herper Tweets: @adamfeuerstein looks mostly like a correction to Friday to me.",2017-03-20 10:44:00-04:00,ESPR,positive
437567.0,Adam Feuerstein Tweets: $ESPR reaction to widely expected regulatory news this morning is puzzling.,2017-03-20 10:41:00-04:00,ESPR,neutral
437568.0,Mid-Morning Market Update: Markets Mostly Flat; Washington Companies Proposes To Acquire  Dominion Diamond,2017-03-20 10:03:00-04:00,ESPR,positive
437569.0,Credit Suisse Upgrades Esperion Therapeutics to Neutral,2017-03-20 09:56:00-04:00,ESPR,positive
437570.0,22 Stocks Moving In Monday's Pre-Market Session,2017-03-20 08:16:00-04:00,ESPR,neutral
437571.0,Esperion Therapeutics Receives FDA Confirmation Regarding Regulatory Pathway To Approval For An LDL-C Lowering Indication For Bempedoic Acid,2017-03-20 07:31:00-04:00,ESPR,positive
437572.0,20 Biggest Mid-Day Losers For Friday,2017-03-17 13:02:00-04:00,ESPR,negative
437573.0,Esperion Falls Victim To Amgen's Poor Repatha Results,2017-03-17 11:09:00-04:00,ESPR,negative
437574.0,Esperion Therapeutics Reports Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin,2017-03-07 08:32:00-05:00,ESPR,neutral
437575.0,Citigroup Upgrades Esperion Therapeutics To Buy,2017-02-28 09:19:00-05:00,ESPR,neutral
437576.0,18 Biggest Mid-Day Gainers For Thursday,2017-02-23 12:48:00-05:00,ESPR,neutral
437577.0,Esperion Reports Q4 EPS $(1.29) vs. $(1.22) Est.,2017-02-22 07:33:00-05:00,ESPR,neutral
437578.0,Esperion Pops to High of $23 on Volume,2017-02-16 09:57:00-05:00,ESPR,neutral
437579.0,Esperion Surge May Be Fueled By Repatha Short Squeeze,2017-02-07 13:28:00-05:00,ESPR,neutral
437580.0,"Esperion, Medicines Company Shares Higher After-Hours; Amgen Said Repatha Reduces Risk of Cardiovascular Events",2017-02-02 18:16:00-05:00,ESPR,neutral
437581.0,Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid,2017-01-08 16:01:00-05:00,ESPR,neutral
437582.0,BZ NOTE: Volatility In Esperion Therapeutics May Be Due To Company Presentation At Stifel Healthcare Conf. Today,2016-11-16 10:27:00-05:00,ESPR,positive
437583.0,Stifel Healthcare Conference Continues Today,2016-11-16 10:26:00-05:00,ESPR,neutral
437584.0,Esperion Spikes to High of $11.31 on Volume,2016-11-16 10:26:00-05:00,ESPR,neutral
437585.0,Esperion Therapeutics Reports Q3 EPS $(0.77) vs. Est. $(0.82),2016-11-03 17:50:00-04:00,ESPR,neutral
437586.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-11-01 11:44:00-04:00,ESPR,neutral
437587.0,10 Biggest Price Target Changes For Friday,2016-10-14 10:24:00-04:00,ESPR,neutral
437588.0,"Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target",2016-10-14 09:22:00-04:00,ESPR,positive
437589.0,Top-Line Data For Esperion's Bempedoic Acid Creates Question About Whether There Is A Place In The Market For It,2016-10-13 16:12:00-04:00,ESPR,positive
437590.0,10 Biggest Mid-Day Gainers For Thursday,2016-10-13 12:29:00-04:00,ESPR,neutral
437591.0,Benzinga's Volume Movers,2016-10-13 10:38:00-04:00,ESPR,neutral
437592.0,"Esperion Therapeutics Reports Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose, Met Primary Endpoint",2016-10-13 07:31:00-04:00,ESPR,neutral
437593.0,"Adam Feuerstein @adamfeuerstein @measured_moves @AndyBiotech Tweet: $ESPR spox tells me study data coming very soon, no specific explanation for missing the September timeline.",2016-10-10 14:58:00-04:00,ESPR,negative
437594.0,13G from BB Biotech on Esperion Therapeutics Shows New 5.1% Stake,2016-09-27 16:24:00-04:00,ESPR,neutral
437595.0,"Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals",2016-09-26 17:17:00-04:00,ESPR,neutral
437596.0,11 Biopharma CEOs To Follow On Twitter,2016-08-18 10:52:00-04:00,ESPR,neutral
437597.0,Esperion Therapeutics Sells off on Volume,2016-08-11 14:03:00-04:00,ESPR,neutral
437598.0,Esperion Therapeutics Reports Q2 $(0.62) vs. Est. $(0.78),2016-08-04 17:44:00-04:00,ESPR,neutral
437599.0,These Five Stocks Have Gotten A Lot Of Attention From Analysts,2016-07-11 16:21:00-04:00,ESPR,neutral
437600.0,"Director McGovern Buys 5,000 Shares of Esperion Therapeutics @$10.00/Share -Form 4",2016-07-07 07:28:00-04:00,ESPR,positive
437601.0,UBS Downgrades Esperion Therapeutics From Buy To Neutral,2016-07-05 09:24:00-04:00,ESPR,neutral
437602.0,Benzinga's Top Downgrades,2016-07-05 09:08:00-04:00,ESPR,positive
437603.0,Wallachbeth Downgrades Esperion Therapeutics to Hold,2016-07-05 07:52:00-04:00,ESPR,neutral
437604.0,Benzinga's Volume Movers,2016-06-30 10:55:00-04:00,ESPR,neutral
437605.0,5 Largest Price Target Changes For Thursday,2016-06-30 10:09:00-04:00,ESPR,neutral
437606.0,Benzinga's Top Downgrades,2016-06-30 09:19:00-04:00,ESPR,positive
437607.0,Esperion Price Target Cut At Citi On U.S. Approval Likelihood,2016-06-30 07:10:00-04:00,ESPR,positive
437608.0,Analysts At Chardan See A 'Pattern Of Missed Guidance' For Esperion Therapeutics,2016-06-29 18:06:00-04:00,ESPR,negative
437609.0,Sharp Downside In Esperion Shares May Be An Overreaction,2016-06-29 17:44:00-04:00,ESPR,negative
437610.0,Esperion Therapeutics Downgraded By JPMorgan After Concerns With FDA Endpoint,2016-06-29 16:39:00-04:00,ESPR,neutral
437611.0,Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Diamond Resorts Shares Climb Following Apollo Deal,2016-06-29 14:43:00-04:00,ESPR,positive
437612.0,7 Biggest Mid-Day Losers For Wednesday,2016-06-29 13:11:00-04:00,ESPR,negative
437613.0,Mid-Day Market Update: Crude Oil Surges 3%; Galena Biopharma Shares Tumble,2016-06-29 12:23:00-04:00,ESPR,negative
437614.0,"Barclays Downgrades Esperion Therapeutics to Equal-weight, Lowers PT to $13.00",2016-06-29 11:37:00-04:00,ESPR,negative
437615.0,Stocks Hitting 52-Week Lows,2016-06-29 10:42:00-04:00,ESPR,negative
437616.0,Mid-Morning Market Update: Markets Open Higher; General Mills Profit Tops Expectations,2016-06-29 10:13:00-04:00,ESPR,positive
437617.0,Esperion Therapeutics Downgraded On Regulatory Concerns By Credit Suisse,2016-06-29 09:44:00-04:00,ESPR,positive
437618.0,8 Largest Price Target Changes For Wednesday,2016-06-29 09:41:00-04:00,ESPR,neutral
437619.0,Benzinga's Top Downgrades,2016-06-29 09:18:00-04:00,ESPR,positive
437620.0,The Market In 5 Minutes: Swoosh And A Miss,2016-06-29 08:43:00-04:00,ESPR,negative
437621.0,13 Stocks Moving In Wednesday's Pre-Market Session,2016-06-29 08:32:00-04:00,ESPR,neutral
437622.0,RBC Capital Downgrades Esperion Therapeutics to Sector Perform,2016-06-29 07:40:00-04:00,ESPR,neutral
437623.0,"Credit Suisse Downgrades Esperion Therapeutics to Underperform, Lowers PT to $10.00",2016-06-29 04:46:00-04:00,ESPR,positive
437624.0,"JP Morgan Downgrades Esperion Therapeutics to Neutral, Lowers PT to $15.00",2016-06-29 04:25:00-04:00,ESPR,positive
437625.0,"4 Stocks Moving In Tuesday's After-Hours Session: Earnings, Buybacks & FDA Setbacks",2016-06-28 16:55:00-04:00,ESPR,neutral
437626.0,Esperion Therapeutics Shares Fall 29% After-Hours to $11.50,2016-06-28 16:13:00-04:00,ESPR,positive
437627.0,Esperion Sees 2016 FY Cash and Cash Equivalents And Investment Securities At $220M by December 31/16,2016-06-28 16:07:00-04:00,ESPR,positive
437628.0,"UPDATE: Esperion Says On Track to Initiate Global Pivotal Phase 3 Studies, CVOT in Q4",2016-06-28 16:07:00-04:00,ESPR,neutral
437629.0,"Esperion Offers Clinical Development, Regulatory Update for Bempedoic Acid",2016-06-28 16:06:00-04:00,ESPR,neutral
437630.0,Adam Feuerstein @adamfeuerstein Tweet: Is there a reason for $ESPR to hold a call tonight?,2016-06-28 16:04:00-04:00,ESPR,neutral
437631.0,Esperion Therapeutics Reports Q1 EPS $(0.65) vs. Est. $(0.74),2016-05-04 08:09:00-04:00,ESPR,neutral
437632.0,Esperion Therapetuics Surges 13%,2016-03-02 11:45:00-05:00,ESPR,neutral
437633.0,"Dir Omenn Buys 5,000 Shares Of Esperion Therapeutics @$15.28/Share -Form 4",2016-03-02 07:25:00-05:00,ESPR,positive
437634.0,"Chardan Capital Maintains Neutral on Esperion Therapeutics, Lowers PT to $13.00",2016-02-26 05:40:00-05:00,ESPR,negative
437635.0,"Chardan Capital Maintains Neutral on Esperion Therapeutics, Lowers PT to $13.00",2016-02-26 03:59:00-05:00,ESPR,negative
437636.0,"Esperion Therapeutics reports Q4 EPS $(0.58) vs $(0.63) Est.; Sees FY16 Cash, Cash Equivalents ~$200M at Year End",2016-02-25 18:03:00-05:00,ESPR,neutral
437637.0,"Barclays Maintains Overweight on Esperion Therapeutics, Lowers PT to $28.00",2016-02-24 05:26:00-05:00,ESPR,negative
437638.0,"Esperion Therapeutics Reports Start of Phase 3 Clinical Program With Long-Term Safety, Tolerability Study",2016-01-13 08:34:00-05:00,ESPR,positive
437639.0,UPDATE: Esperion Therapeutics Expects To Announce Top-Line Results By Mid-Year,2016-01-12 16:09:00-05:00,ESPR,neutral
437640.0,Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy,2016-01-12 16:07:00-05:00,ESPR,neutral
437641.0,S-3 from Esperion Therapeutics Shows Registration for $250M Mixed Securities Shelf Offering,2015-12-22 17:05:00-05:00,ESPR,positive
437642.0,Chardan: Time To Buy The Medicines Co.,2015-11-04 11:06:00-05:00,ESPR,neutral
437643.0,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased",2015-10-13 07:50:00-04:00,ESPR,positive
437644.0,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'",2015-10-12 13:17:00-04:00,ESPR,positive
437645.0,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of  regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'",2015-10-12 13:13:00-04:00,ESPR,negative
437646.0,Benzinga's Volume Movers,2015-10-12 10:29:00-04:00,ESPR,neutral
437647.0,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,2015-10-12 09:56:00-04:00,ESPR,neutral
437648.0,Morning Market Gainers,2015-10-12 09:43:00-04:00,ESPR,neutral
437649.0,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib,2015-10-12 08:14:00-04:00,ESPR,positive
437650.0,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib,2015-10-12 08:11:00-04:00,ESPR,neutral
437651.0,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib",2015-10-12 08:11:00-04:00,ESPR,positive
437652.0,5 Stocks Moving On Friday's After-Hours: From Barracuda To TerraForm,2015-10-03 09:44:00-04:00,ESPR,neutral
437653.0,Morning Market Gainers,2015-09-30 09:41:00-04:00,ESPR,neutral
437654.0,Esperion Therapeutics +11 Premarket Following Chardan Upgrade to Neutral,2015-09-30 08:36:00-04:00,ESPR,neutral
437655.0,"Esperion Therapeutics: Chardan Maintains Negative Bias, Additional Concerns Over ETC-1002 Profile - Says Optimism May Overshoot Reality Of Datasets",2015-09-29 16:37:00-04:00,ESPR,negative
437656.0,"Chardan Capital Upgrades Esperion Therapeutics to Neutral, Lowers PT to $18.00",2015-09-29 16:32:00-04:00,ESPR,negative
437657.0,Morning Market Losers,2015-09-29 10:02:00-04:00,ESPR,negative
437658.0,Benzinga's Top #PreMarket Losers,2015-09-29 08:22:00-04:00,ESPR,negative
437659.0,Esperion Therapeutics -16% Premarket Following Update on ETC-1002 Global Phase 3 Strategy; Analyst PT Cuts,2015-09-29 07:41:00-04:00,ESPR,negative
437660.0,Esperion Therapeutics Gives Further Updates on ETC-1002 Global Phase 3 Strategy Following Receipt of End-of-Phase 2 Meeting Minutes,2015-09-28 16:30:00-04:00,ESPR,neutral
437661.0,Benzinga's Top Downgrades,2015-08-19 10:28:00-04:00,ESPR,positive
437662.0,Morning Market Losers,2015-08-19 09:52:00-04:00,ESPR,negative
437663.0,Benzinga's Top #PreMarket Losers,2015-08-19 08:22:00-04:00,ESPR,negative
437664.0,Needham Downgrades Esperion Therapeutics to Strong Buy,2015-08-19 07:46:00-04:00,ESPR,positive
437665.0,Morning Market Gainers,2015-08-18 09:38:00-04:00,ESPR,neutral
437666.0,Benzinga's Top #PreMarket Gainers,2015-08-18 08:15:00-04:00,ESPR,positive
437667.0,Watch These After-Hours Movers On Tuesday,2015-08-18 07:46:00-04:00,ESPR,neutral
437668.0,Esperion Offers Update on ETC-1002 Development Program: Says On Track to Begin Phase 3 Trial by Year End '15,2015-08-17 16:07:00-04:00,ESPR,neutral
437669.0,Needham Upgrades Esperion Therapeutics to Strong Buy,2015-08-10 07:52:00-04:00,ESPR,positive
437670.0,Chardan: Esperion Therapeutics Still A Sell,2015-08-07 11:30:00-04:00,ESPR,neutral
437671.0,5 Biotechs With Catalysts Coming This Week,2015-08-03 16:59:00-04:00,ESPR,neutral
437672.0,"Chardan Reiterates Sell On Esperion, Cites 'Lack Of Visibility' And 'Possibility Of Declining Efficacy'",2015-07-28 11:52:00-04:00,ESPR,negative
437673.0,Benzinga's Top #PreMarket Gainers,2015-07-28 08:14:00-04:00,ESPR,positive
437674.0,Esperion +6% as Co Reported Top-Line Phase 2 Results for ETC-1002,2015-07-28 07:55:00-04:00,ESPR,neutral
437675.0,Esperion Therapeutics Reports Top-Line Phase 2 Results for ETC-1002 Met Primary Endpoint,2015-07-28 07:33:00-04:00,ESPR,neutral
437676.0,"Biotech Stocks Falling Broadly, Here's Why And How Much",2015-07-26 21:57:00-04:00,ESPR,negative
437677.0,Traders Attributing Esperion Price Drop To Regeneron News,2015-07-24 14:27:00-04:00,ESPR,negative
437678.0,Esperion Spikes Lower,2015-07-24 14:27:00-04:00,ESPR,negative
437679.0,"Chardan Reiterates Sell On Esperion Therapeutics, Sees At Least 6 Reasons To Beware",2015-07-08 08:57:00-04:00,ESPR,neutral
437680.0,Esperion Therapeutics Shares +4% Premarket After Co Announces Removal of 240 mg Partial Clinical Hold for ETC-1002,2015-07-07 08:18:00-04:00,ESPR,positive
437681.0,Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002,2015-07-07 08:02:00-04:00,ESPR,neutral
437682.0,5 Biotech Stocks On Deck With The FDA,2015-06-30 13:39:00-04:00,ESPR,neutral
437683.0,Esperion Shares Spike to High on Volume,2015-06-30 12:19:00-04:00,ESPR,positive
437684.0,JP Morgan Initiates Esperion Therapeutics With Overweight,2015-06-25 09:07:00-04:00,ESPR,neutral
437685.0,Benzinga's Top Initiations,2015-06-25 09:02:00-04:00,ESPR,positive
437686.0,"JP Morgan Initiates Coverage on Esperion Therapeutics at Overweight, Announces $130.00 PT",2015-06-25 06:47:00-04:00,ESPR,neutral
437687.0,Benzinga's Top Downgrades,2015-06-24 10:11:00-04:00,ESPR,positive
437688.0,Credit Suisse Downgrades Esperion Therapeutics To Neutral,2015-06-24 09:50:00-04:00,ESPR,positive
437689.0,"Credit Suisse: Esperion Therapeutics' Long-Term Potential Is 'Robust,' But More Clarity Needed",2015-06-24 07:34:00-04:00,ESPR,positive
437690.0,"Credit Suisse Downgrades Esperion Therapeutics to Neutral, Lowers PT to $86.00",2015-06-24 07:03:00-04:00,ESPR,positive
437691.0,"Credit Suisse Assumes Esperion Therapeutics at Neutral, Lowers $86.00 PT",2015-06-23 17:59:00-04:00,ESPR,positive
437692.0,Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers,2015-06-23 17:32:00-04:00,ESPR,neutral
437693.0,"Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors",2015-06-15 08:33:00-04:00,ESPR,neutral
437694.0,Morning Market Losers,2015-06-10 09:45:00-04:00,ESPR,negative
437695.0,Benzinga's Top #PreMarket Losers,2015-06-10 08:17:00-04:00,ESPR,negative
437696.0,"Esperion Shares Rise 5% Premarket; JMP Securities Raised PT from $121 to $177, Maintaining Outperform Rating",2015-06-03 09:08:00-04:00,ESPR,positive
437697.0,Morning Market Losers,2015-05-22 09:55:00-04:00,ESPR,negative
437698.0,4 SMID-Cap Biotechs Barclays Just Confessed It Loves,2015-05-21 09:00:00-04:00,ESPR,positive
437699.0,"Barclays Initiates Coverage on Esperion Therapeutics at Overweight, Announces $150.00 PT",2015-05-21 06:13:00-04:00,ESPR,negative
437700.0,"Barclays Initiates Coverage on Esperion Therapeutics at Overweight, Announces $150.00 PT",2015-05-21 04:12:00-04:00,ESPR,negative
437701.0,7 Biotech Stocks Moving Off The UBS Healthcare Conference,2015-05-19 14:16:00-04:00,ESPR,neutral
437702.0,Esperion Therapeutics Reports Q1 Loss of $0.56/Share; 8-K Shows Co. Expecting Topline Results from Phase 2 Study of ETC-1002-014 by Mid '15,2015-05-07 16:52:00-04:00,ESPR,negative
437703.0,3 Diverse Stocks This Expert Is Watching (In 3 Charts),2015-04-21 15:19:00-04:00,ESPR,neutral
437704.0,Esperion Shares Spike Higher on Volume,2015-04-13 11:28:00-04:00,ESPR,positive
437705.0,These 5 Stocks Have More Than Doubled In 2015,2015-04-06 09:00:00-04:00,ESPR,neutral
437706.0,Morning Market Gainers,2015-04-01 09:42:00-04:00,ESPR,neutral
437707.0,Here's Why Esperion Therapeutics Is Rocketing Higher,2015-04-01 09:25:00-04:00,ESPR,neutral
437708.0,UBS Initiates Esperion Therapeutics With Buy,2015-04-01 09:16:00-04:00,ESPR,neutral
437709.0,Benzinga's Top Initiations,2015-04-01 08:59:00-04:00,ESPR,positive
437710.0,Benzinga's Top #PreMarket Gainers,2015-04-01 08:09:00-04:00,ESPR,positive
437711.0,"UBS Initiates Coverage on Esperion Therapeutics at Buy, Announces $140.00 PT",2015-04-01 06:22:00-04:00,ESPR,neutral
437712.0,Is Esperion Therapeutics Worth $130? This Analyst Thinks So,2015-03-27 18:17:00-04:00,ESPR,positive
437713.0,Morning Market Gainers,2015-03-27 09:43:00-04:00,ESPR,neutral
437714.0,"Citigroup Assumes Esperion Therapeutics at Buy, Announces $130.00 PT",2015-03-27 06:23:00-04:00,ESPR,neutral
437715.0,13D Filing Shows Esperion Therapeutics Holder Domain Partners Raises Stake From 10.29% To 11.2%,2015-03-25 16:49:00-04:00,ESPR,neutral
437716.0,Pro: Esperion Therapeutics Shares Could Double,2015-03-21 15:27:00-04:00,ESPR,positive
437717.0,Benzinga's Volume Movers,2015-03-19 10:37:00-04:00,ESPR,neutral
437718.0,Morning Market Gainers,2015-03-19 10:02:00-04:00,ESPR,neutral
437719.0,Benzinga's Top #PreMarket Gainers,2015-03-19 08:13:00-04:00,ESPR,positive
437720.0,Esperion Therapeutics Shares Fall 2% Premarket Following Pricing of 1.75M Share Offering @$100.00/Share,2015-03-19 07:17:00-04:00,ESPR,positive
437721.0,"Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More",2015-03-17 20:31:00-04:00,ESPR,neutral
437722.0,Esperion Therapeutics Announces $150M Offering,2015-03-17 17:30:00-04:00,ESPR,neutral
437723.0,Benzinga's Volume Movers,2015-03-17 10:27:00-04:00,ESPR,neutral
437724.0,Esperion Therapeutics Says ETC-1002-009 Study Met Primary Endpoint,2015-03-17 07:33:00-04:00,ESPR,neutral
437725.0,Stocks Hitting 52-Week Highs,2015-02-09 10:15:00-05:00,ESPR,neutral
437726.0,"Esperion Therapeutics Spokesperson Says Co Pleased With PT Raise by Credit Suisse, Says Recognizes Value We Think We Have in ETC-1002",2015-02-03 12:45:00-05:00,ESPR,positive
437727.0,Mid-Morning Market Update: Markets Open Higher; AutoNation Profit Beats Views,2015-02-03 10:55:00-05:00,ESPR,positive
437728.0,Benzinga's Volume Movers,2015-02-03 10:34:00-05:00,ESPR,neutral
437729.0,Stocks Hitting 52-Week Highs,2015-02-03 10:21:00-05:00,ESPR,neutral
437730.0,Morning Market Gainers,2015-02-03 09:45:00-05:00,ESPR,neutral
437731.0,"Esperion Therapeutics Shares Rise ~18% Premarket on Credit Suisse Comments that Co is Likely Acquisition Target, Raises PT to $100 from $41",2015-02-03 08:46:00-05:00,ESPR,positive
437732.0,"Credit Suisse Sees Esperion Therapeutics Likely Acquisition, Raises PT To $100 From $41",2015-02-03 07:21:00-05:00,ESPR,positive
437733.0,"Bank of America Upgrades Esperion Therapeutics to Buy, Raises PT to $60.00",2015-01-21 11:43:00-05:00,ESPR,neutral
437734.0,UPDATE: JMP Securities Reiterates On Esperion Therapeutics On Minimal Risks,2015-01-05 10:00:00-05:00,ESPR,neutral
437735.0,Esperion Therapeutics Declines Comment on Move in Share Price,2014-12-30 13:52:00-05:00,ESPR,positive
437736.0,S-3 from Esperion Therapeutics Shows Registration for $200M Mixed Securities Shelf Offering,2014-12-22 16:46:00-05:00,ESPR,positive
437737.0,"Credit Suisse Maintains Outperform on Esperion Therapeutics, Raises PT to $41.00",2014-12-04 04:32:00-05:00,ESPR,positive
437738.0,Benzinga's Volume Movers,2014-10-27 10:41:00-04:00,ESPR,neutral
437739.0,Morning Market Losers ,2014-10-16 09:52:00-04:00,ESPR,negative
437740.0,Benzinga's Top #PreMarket Losers,2014-10-16 08:12:00-04:00,ESPR,negative
437741.0,Esperion Therapeutics Prices 4.25M Share Offering @$20.00/Share,2014-10-15 20:02:00-04:00,ESPR,positive
437742.0,Esperion Therapeutics Announces $85M Proposed Public Offering of Common Stock ,2014-10-14 16:09:00-04:00,ESPR,neutral
437743.0,Markets Mixed; Constellation Brands Posts Downbeat Profit,2014-10-02 10:38:00-04:00,ESPR,positive
437744.0,Stocks Hitting 52-Week Highs,2014-10-02 10:16:00-04:00,ESPR,neutral
437745.0,UPDATE: JMP Securities Reiterates On Esperion Therapeutics Inc Following Positive Trial Results,2014-10-02 10:05:00-04:00,ESPR,positive
437746.0,Morning Market Movers ,2014-10-02 09:44:00-04:00,ESPR,neutral
437747.0,UPDATE: Credit Suisse Reiterates On Esperion Therapeutics Inc On Multiple Positive Factors,2014-10-02 08:51:00-04:00,ESPR,positive
437748.0,Benzinga's Top #PreMarket Gainers ,2014-10-02 08:38:00-04:00,ESPR,positive
437749.0,"JMP Securities Maintains Market Outperform on Esperion Therapeutics, Raises PT to $53.00",2014-10-02 08:25:00-04:00,ESPR,positive
437750.0,"Credit Suisse Maintains Outperform on Esperion Therapeutics, Raises PT to $38.00",2014-10-02 06:26:00-04:00,ESPR,positive
437751.0,UPDATE: Esperion Therapeutics Reports Results of Trial Met Primary Endpoint,2014-10-01 16:19:00-04:00,ESPR,neutral
437752.0,Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002 ,2014-10-01 16:18:00-04:00,ESPR,positive
437753.0,"Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002, An Investigational Therapy For Patients With Hypercholesterolemia",2014-10-01 16:15:00-04:00,ESPR,positive
437754.0,"Esperion Therapeutics Reports Q2 EPS of $(0.60), Inline",2014-08-12 08:06:00-04:00,ESPR,neutral
437755.0,Esperion Therapeutics Says Top-Line Results Expected in Early October from Phase 2B ETC-1002-008 Clinical Trial in Statin Intolerant Patients,2014-08-12 06:10:00-04:00,ESPR,neutral
437756.0,Esperion Therapeutics Announces Initiation of Phase 2 ETC-1002 Study,2014-07-24 08:07:00-04:00,ESPR,neutral
437757.0,Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results,2014-02-26 16:34:00-05:00,ESPR,neutral
437758.0,Shares of Esperion Therapeutics Up ~4% Since 13G Filing from Pfizer Disclosing Unch Position at 6.29%,2014-02-13 14:44:00-05:00,ESPR,positive
437759.0,Esperion Therapeutics Reports Q3 EPS of $(0.34) vs $(0.40) Est,2013-11-06 16:43:00-05:00,ESPR,neutral
437760.0,Esperion Therapeutics Reports Q2 GAAP EPS of $(19.82) Which May Not Compare $(0.53) Est,2013-08-12 08:20:00-04:00,ESPR,neutral
437761.0,"Credit Suisse Initiates Coverage on Esperion Therapeutics at Outperform, Announces $23.00 PT",2013-07-22 09:46:00-04:00,ESPR,positive
437762.0,UPDATE: Stifel Nicolaus Initiates Esperion Therapeutics at Buy on ETC-1002 Potential,2013-07-22 08:48:00-04:00,ESPR,neutral
437763.0,"Credit Suisse Initiates Coverage on Esperion Therapeutics at Outperform, Announces $23.00 PT",2013-07-22 08:43:00-04:00,ESPR,positive
437764.0,"Citigroup Initiates Coverage on Esperion Therapeutics at Buy, Announces $30.00 PT",2013-07-22 08:42:00-04:00,ESPR,neutral
437765.0,"Stifel Nicolaus Initiates Coverage on Esperion Therapeutics at Buy, Announces $24.00 PT",2013-07-22 08:25:00-04:00,ESPR,neutral
437766.0,"Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering ",2013-07-11 16:00:00-04:00,ESPR,neutral
437767.0,"Esperion Therapeutics Shares Open at $17 After Pricing at $14, Moving Higher, Now at $17.23",2013-06-26 10:41:00-04:00,ESPR,positive
437768.0,"IPO for Esperion Therapeutics to Open for Quote at 10:25AM EDT, Expected to Open at 10:40AM",2013-06-26 08:44:00-04:00,ESPR,neutral
437769.0,Esperion Therapeutics Prices 5M Share IPO at $14 per Share,2013-06-26 08:04:00-04:00,ESPR,positive
437770.0,Esperion Therapeutics Files $70M IPO,2013-05-14 16:38:00-04:00,ESPR,neutral
